A

AEON Biopharma Inc
AMEX:AEON

Watchlist Manager
AEON Biopharma Inc
AMEX:AEON
Watchlist
Price: 1 USD 5.37%
Market Cap: $24m

AEON Biopharma Inc
Investor Relations

AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Marc Forth
Principal Financial Officer, President, CEO & Director
No Bio Available
Mr. Alex Wilson
Executive VP, Chief Legal Officer & Corporate Secretary
No Bio Available
Dr. Chad K. Oh M.D.
Chief Medical Officer
No Bio Available
Ms. Jennifer Sy
Principal Accounting Officer
No Bio Available

Contacts

Address
CALIFORNIA
Newport Beach
4040 Macarthur Boulevard, Suite 310
Contacts